Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin in Overweight Insulin-Resistant Type 1 Diabetes
NCT05035368Phase 2Withdrawn
- Sponsor
- Dompé
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ladarixin in type 1 diabetes mellitus (T1D), sponsored by Dompé. Planned start Sep 2021; status: withdrawn.
02
Drugs
ladarixin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05035368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035368.